Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?

REFERENCES 1. Amir E, Seruga B, Freedman O, et al: Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? J Clin Oncol 27:1919, 2009 2. Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008 3. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008 4. Geyer C, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 5. Press M, Finn R, Cameron D, et al: HER2 gene amplification, HER2 and EGFR messenger RNA and protein expression and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861-7870, 2008